Eliot Corday M.D., F.C.C.P. , John K. Vyden M.B.B.S. , Tzu-Wang Lang M.D. , Erno Boszormenyi M.D. , Marciano Carvalho M.D. , Herbert Gold M.D., F.C.C.P. , Alfred Goldman M.D., F.C.C.P. , Eduardo Rosselot M.D.
{"title":"Reevaluation of the Treatment of Shock Secondary to Cardiac Infarction","authors":"Eliot Corday M.D., F.C.C.P. , John K. Vyden M.B.B.S. , Tzu-Wang Lang M.D. , Erno Boszormenyi M.D. , Marciano Carvalho M.D. , Herbert Gold M.D., F.C.C.P. , Alfred Goldman M.D., F.C.C.P. , Eduardo Rosselot M.D.","doi":"10.1378/chest.56.3.200","DOIUrl":null,"url":null,"abstract":"<div><p>When given early vasopressor<span> drugs can be an effective from of therapy for cardiogenic shock because they increase coronary blood flow, cardiac output and blood pressure. They vasodilate the coronary vascular bed and in 40 percent of the experiments, reduce total peripheral vascular resistance. The use of 3-hydroxytyramine and the vasopressor-vasodilator combination provide most effective coronary and regional perfusion to other vital organs. New mechanical circulatory assistance techniques applied to the treatment of irreversible cardiogenic shock promise that the high mortality rate associated with this dreaded complication will be reduced.</span></p></div>","PeriodicalId":11305,"journal":{"name":"Diseases of the chest","volume":"56 3","pages":"Pages 200-209"},"PeriodicalIF":0.0000,"publicationDate":"1969-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1378/chest.56.3.200","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diseases of the chest","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0096021715345453","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5
Abstract
When given early vasopressor drugs can be an effective from of therapy for cardiogenic shock because they increase coronary blood flow, cardiac output and blood pressure. They vasodilate the coronary vascular bed and in 40 percent of the experiments, reduce total peripheral vascular resistance. The use of 3-hydroxytyramine and the vasopressor-vasodilator combination provide most effective coronary and regional perfusion to other vital organs. New mechanical circulatory assistance techniques applied to the treatment of irreversible cardiogenic shock promise that the high mortality rate associated with this dreaded complication will be reduced.